Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology | Hematology
 Disease Category: Lymphocytic Leukemia, Acute
Location: United States, CA

Trial Information

COG AALL07P1: A Phase II Pilot Trial of Bortezomib (PS-341, Velcade, IND#58,443) in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymhoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)

The aims of this study are to improve treatment for relapsed ALL. However, LL has been shown to respond to chemotherapy in a similar way to ALL and is often treated as a leukemia. Therefore, we think that the therapy may also have an effect on LL.

The overall goal of this study is to find out if bortezomib can be safely added to the standard COG Re-Induction therapy for relapsed ALL, and be an effective therapy.

Patient Inclusion/Exclusion Criteria:


- See http://clinicaltrials.coh.org for additional information.


City of Hope
1500 East Duarte Road
Duarte, CA 91010-3000
Phone: 866-896-HOPE (4673)

View Map

Research Center Information: City of Hope

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.